Technology
FARO Announces Second Quarter Financial Results
Published
5 months agoon
By
Revenue of $82.1 millionGross margin of 54.6%; Non-GAAP gross margin 55.0%, above guidance rangeLoss per share of $(0.03); Non-GAAP earnings per share (“EPS”) of $0.18, above guidance rangeCash flow from operations of $4.2 million
LAKE MARY, Fla., Aug. 8, 2024 /PRNewswire/ — FARO® Technologies, Inc. (Nasdaq: FARO), a global leader in 4D digital reality solutions, today announced its financial results for the second quarter ended June 30, 2024.
“As I reflect on the completion of my first year at FARO, I am pleased with the execution of the first phase of our journey to drive operational excellence and we are pacing well ahead of our expectations,” said Peter Lau, President & Chief Executive Officer. “By continuing to build a strong base of financial performance, marked by consistent EBITDA and free cash flow generation, we are investing in several multi-year value creation activities. Against the backdrop of a difficult macroeconomic environment, FARO delivered GAAP net loss of $0.5 million and $8.4 million of adjusted EBITDA, or 10.3% of revenue, concluding a first half of 2024 adjusted EBITDA that exceeded full year fiscal 2023 adjusted EBITDA. Looking forward, we are excited about the next phase in our journey, as we communicated in March, to deliver on the key organic growth plans which our operational improvements has enabled.”
Second Quarter 2024 Financial Summary
Total sales of $82.1 million, down 7% year over yearGross margin of 54.6%, compared to 37.8% in the prior year periodNon-GAAP gross margin of 55.0%, compared to 38.7% in the prior year periodOperating expenses of $43.0 million, compared to $58.7 million in the prior year periodNon-GAAP operating expenses of $40.0 million, compared to $44.1 million in the prior year periodNet loss of $0.5 million, or $(0.03) per share compared to net loss of $28.2 million, or $(1.49) per share in the prior year periodNon-GAAP net income of $3.4 million, or $0.18 per share compared to non-GAAP net loss of $10.8 million, or $(0.57) per share in the prior year periodAdjusted EBITDA of $8.4 million, or 10.3% of total sales compared to $(7.2) million, or (1.0%) of total sales in the prior year periodCash, cash equivalents & short-term investments of $97.9 million compared to $96.3 million as of December 31, 2023
* A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is provided in the financial schedules portion at the end of this press release. An additional explanation of these measures is included below under the heading “Non-GAAP Financial Measures”.
Outlook for the Third Quarter 2024
For the third quarter ending September 30, 2024, FARO currently expects:
Revenue in the range of $76 to $84 millionGross margin in the range of 53.0% to 54.5%. Non-GAAP gross margin in the range of 53.5% to 55.0%Operating expenses in the range of $45 to $47 million. Non-GAAP operating expenses in the range of $40 to $42 millionNet loss per share in the range of ($0.32) to ($0.12). Non-GAAP net loss to net income per share in the range of $(0.01) to $0.19.
Conference Call
The Company will host a conference call to discuss these results on Thursday, August 8, 2024, at 4:30 p.m. ET. Interested parties can access the conference call by dialing (800) 267-6316 (U.S.) or +1 (203) 518-9783 (International) and using the passcode FARO. A live webcast will be available in the Investor Relations section of FARO’s website at: https://www.faro.com/en/About-Us/Investor-Relations/Financial-Events-and-Presentations
A replay webcast will be available in the Investor Relations section of the Company’s web site approximately two hours after the conclusion of the call and will remain available for approximately 30 calendar days.
About FARO
For over 40 years, FARO has provided industry-leading technology solutions that enable customers to measure their world, and then use that data to make smarter decisions faster. FARO continues to be a pioneer in bridging the digital and physical worlds through data-driven reliable accuracy, precision, and immediacy. For more information, visit www.faro.com.
Non-GAAP Financial Measures
This press release contains information about our financial results that are not presented in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures, including non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income (loss) from operations, non-GAAP net income (loss) and non-GAAP net income (loss) per share, exclude the impact of purchase accounting intangible amortization expense, stock-based compensation, restructuring and other charges, and other tax adjustments, and are provided to enhance investors’ overall understanding of our historical operations and financial performance.
In addition, we present EBITDA, which is calculated as net income (loss) before interest (income) expense, net, income tax benefit (expense) and depreciation and amortization, and Adjusted EBITDA, which is calculated as EBITDA, excluding other (income) expense, net, stock-based compensation, and restructuring and other charges, as measures of our operating profitability. The most directly comparable GAAP measure to EBITDA and Adjusted EBITDA is net income (loss). We also present Adjusted EBITDA margin, which is calculated as Adjusted EBITDA as a percent of total sales.
We have included non-GAAP total sales on a constant currency basis. The most directly comparable GAAP measure to total sales on a constant currency basis is total sales. We believe constant currency information is useful in analyzing underlying trends in our business and the commercial performance of our products by eliminating the impact of highly volatile fluctuations in foreign currency markets and allows for period-to-period comparisons of our performance. For simplicity, we may elect to omit this information in future periods if we determine a lack of material impact. To present this information, current period performance for entities reporting in currencies other than U.S. dollars are converted to U.S. dollars at the exchange rate in effect during the last day of the prior comparable period.
Management believes that these non-GAAP financial measures provide investors with relevant period-to-period comparisons of our core operations using the same methodology that management employs in its review of the Company’s operating results. These financial measures are not recognized terms under GAAP and should not be considered in isolation or as a substitute for a measure of financial performance prepared in accordance with GAAP.
These non-GAAP financial measures have limitations that should be considered before using these measures to evaluate a company’s financial performance. These non-GAAP financial measures, as presented, may not be comparable to similarly titled measures of other companies due to varying methods of calculation. The financial statement tables that accompany this press release include a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, such as statements about the outlook for the third quarter of 2024, demand for and customer acceptance of FARO’s products, FARO’s product development and product launches, FARO’s growth, strategic and restructuring plans and initiatives, including but not limited to the additional restructuring charges expected to be incurred in connection with our restructuring and integration plans and the timing and amount of cost savings and other benefits expected to be realized from the restructuring and integration plans and other strategic initiatives, and FARO’s growth potential and profitability. Statements that are not historical facts or that describe the Company’s plans, objectives, projections, expectations, assumptions, strategies, or goals are forward-looking statements. In addition, words such as “is,” “will” and similar expressions or discussions of FARO’s plans or other intentions identify forward-looking statements. Forward-looking statements are not guarantees of future performance and are subject to various known and unknown risks, uncertainties, and other factors that may cause actual results, performances, or achievements to differ materially from future results, performances, or achievements expressed or implied by such forward-looking statements. Consequently, undue reliance should not be placed on these forward-looking statements.
Factors that could cause actual results to differ materially from what is expressed or forecasted in such forward-looking statements include, but are not limited to:
the Company’s ability to realize the intended benefits of its undertaking to transition to a company that is reorganized around functions to improve the efficiency of its sales organization and to improve operational effectiveness;the Company’s inability to successfully execute its strategic plan, restructuring plan and integration plan, including but not limited to additional impairment charges and/or higher than expected severance costs and exit costs, and its inability to realize the expected benefits of such plans;the changes in our executive management team in 2023 and 2024 and the loss of any of our executive officers or other key personnel, which may be impacted by factors such as our inability to competitively address inflationary pressures on employee compensation and flexibility in employee work arrangements;the outcome of any litigation to which the Company is or may become a party;loss of future government sales;potential impacts on customer and supplier relationships and the Company’s reputation;development by others of new or improved products, processes or technologies that make the Company’s products less competitive or obsolete;the Company’s inability to maintain its technological advantage by developing new products and enhancing its existing products;declines or other adverse changes, or lack of improvement, in industries that the Company serves or the domestic and international economies in the regions of the world where the Company operates and other general economic, business, and financial conditions;the effect of general economic and financial market conditions, including in response to public health concerns;assumptions regarding the Company’s financial condition or future financial performance may be incorrect;the impact of fluctuations in foreign exchange rates and inflation rates; andother risks and uncertainties discussed in Part I, Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 28, 2024, as supplemented by the Company’s Quarterly Reports on Form 10-Q, and in other SEC filings.
Forward-looking statements in this release represent the Company’s judgment as of the date of this release. The Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, unless otherwise required by law.
FARO TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months Ended
Six Months Ended
(in thousands, except share and per share data)
June 30, 2024
June 30, 2023
June 30, 2024
June 30, 2023
Sales
Product
$ 61,312
$ 67,603
$ 124,848
$ 132,843
Service
20,773
20,608
41,481
40,335
Total sales
82,085
88,211
166,329
173,178
Cost of sales
Product
26,119
44,094
56,571
78,051
Service
11,177
10,794
21,662
22,088
Total cost of sales
37,296
54,888
78,233
100,139
Gross profit
44,789
33,323
88,096
73,039
Operating expenses
Selling, general and administrative
32,590
38,561
72,183
79,937
Research and development
9,833
11,662
18,857
24,380
Restructuring costs
616
8,450
616
12,688
Total operating expenses
43,039
58,673
91,656
117,005
Income (loss) from operations
1,750
(25,350)
(3,560)
(43,966)
Other (income) expense
Interest expense
761
1,003
1,592
1,838
Other income (expense), net
(43)
476
(18)
256
Income (loss) before income tax
1,032
(26,829)
(5,134)
(46,060)
Income tax expense
1,556
1,416
2,657
3,349
Net loss
$ (524)
$ (28,245)
$ (7,791)
$ (49,409)
Net loss per share – Basic
$ (0.03)
$ (1.49)
$ (0.41)
$ (2.62)
Net loss per share – Diluted
$ (0.03)
$ (1.49)
$ (0.41)
$ (2.62)
Weighted average shares – Basic
19,293,778
18,920,675
19,183,822
18,871,007
Weighted average shares – Diluted
19,293,778
18,920,675
19,183,822
18,871,007
FARO TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(in thousands, except share and per share data)
June 30,
2024
December 31,
2023
ASSETS
Current assets:
Cash and cash equivalents
$ 97,914
$ 76,787
Short-term investments
—
19,496
Accounts receivable, net
84,868
92,028
Inventories, net
34,409
34,529
Prepaid expenses and other current assets
30,468
38,768
Total current assets
247,659
261,608
Non-current assets:
Property, plant and equipment, net
18,412
21,181
Operating lease right-of-use assets
10,960
12,231
Goodwill
108,164
109,534
Intangible assets, net
46,135
47,891
Service and sales demonstration inventory, net
21,044
23,147
Deferred income tax assets, net
24,792
25,027
Other long-term assets
3,915
4,073
Total assets
$ 481,081
$ 504,692
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable
$ 27,867
$ 27,404
Accrued liabilities
25,373
29,930
Income taxes payable
3,227
5,699
Current portion of unearned service revenues
40,014
40,555
Customer deposits
5,208
4,251
Lease liabilities
4,645
5,434
Total current liabilities
106,334
113,273
Loan – 5.50% Convertible Senior Notes
69,983
72,760
Unearned service revenues – less current portion
19,984
20,256
Lease liabilities – less current portion
9,556
10,837
Deferred income tax liabilities
12,498
13,308
Income taxes payable – less current portion
6,114
5,629
Other long-term liabilities
16
23
Total liabilities
224,485
236,086
Commitments and contingencies
Shareholders’ equity:
Common stock – par value $0.001, 50,000,000 shares authorized;
20,779,711 and 20,343,359 issued, respectively; 19,406,669 and 18,968,798
outstanding, respectively
20
20
Additional paid-in capital
351,849
346,277
Retained earnings
(17,580)
(9,789)
Accumulated other comprehensive loss
(47,038)
(37,247)
Common stock in treasury, at cost – 1,373,042 and 1,374,561 shares held,
respectively
(30,655)
(30,655)
Total shareholders’ equity
256,596
268,606
Total liabilities and shareholders’ equity
$ 481,081
$ 504,692
FARO TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended June 30,
(in thousands)
2024
2023
Cash flows from:
Operating activities:
Net loss
$ (7,791)
$ (49,409)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
7,788
7,925
Stock-based compensation
5,703
8,584
Inventory write-downs
—
8,132
Asset impairment charges
—
4,571
Deferred income tax (benefit) and other non-cash charges
(1,327)
(41)
Provision for excess and obsolete inventory
490
1,033
Amortization of debt discount and issuance costs
223
181
Loss on disposal of assets
994
130
Provisions for bad debts, net of recoveries
304
408
Change in operating assets and liabilities:
Decrease (Increase) in:
Accounts receivable
3,943
3,280
Inventories
(3,764)
1,587
Prepaid expenses and other current assets
7,771
3,105
(Decrease) Increase in:
Accounts payable and accrued liabilities
(3,087)
(277)
Income taxes payable
(1,853)
(263)
Customer deposits
1,126
(1,210)
Unearned service revenues
965
(750)
Other liabilities
(698)
(193)
Net cash provided by (used in) operating activities
10,787
(13,207)
Investing activities:
Purchases of property and equipment
(1,688)
(4,312)
Maturity of short-term investments
20,009
(20,024)
Cash paid for technology development, patents and licenses
(3,392)
(3,616)
Net cash provided by (used in) investing activities
14,929
(27,952)
Financing activities:
Payments on finance leases
(109)
(105)
Cash settlement of equity awards
—
(277)
Proceeds from issuance of 5.50% Convertible Senior Notes, due 2028, net of discount,
issuance cost and accrued interest
—
72,310
Repayment of 5.50% Convertible Senior Notes, due 2028
(2,685)
—
Net cash (used in) provided by financing activities
(2,794)
71,928
Effect of exchange rate changes on cash and cash equivalents
(1,795)
(353)
Increase in cash and cash equivalents
21,127
30,416
Cash and cash equivalents, beginning of period
76,787
37,812
Cash and cash equivalents, end of period
$ 97,914
$ 68,228
FARO TECHNOLOGIES, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP TO NON-GAAP
(UNAUDITED)
Three Months Ended June 30,
Six Months Ended June 30,
(dollars in thousands, except per share data)
2024
2023
2024
2023
Gross profit, as reported
$ 44,789
$ 33,323
$ 88,096
$ 73,039
Stock-based compensation (1)
374
419
704
691
Restructuring and other costs (2)
—
435
3
870
Non-GAAP adjustments to gross profit
374
854
707
1,561
Non-GAAP gross profit
$ 45,163
$ 34,177
$ 88,803
$ 74,600
Gross margin, as reported
54.6 %
37.8 %
53.0 %
42.2 %
Non-GAAP gross margin
55.0 %
38.7 %
53.4 %
43.1 %
Selling, general and administrative, as reported
$ 32,590
$ 38,561
$ 72,183
$ 79,937
Stock-based compensation (1)
(196)
(3,554)
(4,138)
(6,122)
Restructuring and other costs (2)
(745)
(359)
(3,453)
(1,154)
Purchase accounting intangible amortization
(341)
(688)
(884)
(1,361)
Non-GAAP selling, general and administrative
$ 31,308
$ 33,960
$ 63,708
$ 71,300
Research and development, as reported
$ 9,833
$ 11,662
$ 18,857
$ 24,380
Stock-based compensation (1)
(594)
(977)
(861)
(1,771)
Purchase accounting intangible amortization
(515)
(541)
(1,004)
(1,040)
Non-GAAP research and development
$ 8,724
$ 10,144
$ 16,992
$ 21,569
Operating expenses, as reported
$ 43,039
$ 58,673
$ 91,656
$ 117,005
Stock-based compensation (1)
(790)
(4,531)
(4,999)
(7,893)
Restructuring and other costs (2)
(1,361)
(8,809)
(4,069)
(13,842)
Purchase accounting intangible amortization
(856)
(1,229)
(1,888)
(2,401)
Non-GAAP adjustments to operating expenses
(3,007)
(14,569)
(10,956)
(24,136)
Non-GAAP operating expenses
$ 40,032
$ 44,104
$ 80,700
$ 92,869
Income (loss) from operations, as reported
$ 1,750
$ (25,350)
$ (3,560)
$ (43,966)
Non-GAAP adjustments to gross profit
374
854
707
1,561
Non-GAAP adjustments to operating expenses
3,007
14,569
10,956
24,136
Non-GAAP income (loss) from operations
$ 5,131
$ (9,927)
$ 8,103
$ (18,269)
Net loss, as reported
$ (524)
$ (28,245)
$ (7,791)
$ (49,409)
Non-GAAP adjustments to gross profit
374
854
707
1,561
Non-GAAP adjustments to operating expenses
3,007
14,569
10,956
24,136
Income tax effect of non-GAAP adjustments (3)
(641)
(5,888)
(2,713)
(8,457)
Other tax adjustments (3)
1,146
7,959
3,894
14,342
Non-GAAP net income (loss)
$ 3,362
$ (10,751)
$ 5,053
$ (17,827)
Net loss per share – Diluted, as reported
$ (0.03)
$ (1.49)
$ (0.41)
$ (2.62)
Stock-based compensation (1)
0.06
0.26
0.30
0.46
Restructuring and other costs (2)
0.07
0.49
0.21
0.78
Purchase accounting intangible amortization
0.05
0.06
0.10
0.13
Income tax effect of non-GAAP adjustments (3)
(0.03)
(0.31)
(0.14)
(0.45)
Other tax adjustments (3)
0.06
0.42
0.20
0.76
Non-GAAP net income (loss) per share – Diluted
$ 0.18
$ (0.57)
$ 0.26
$ (0.94)
(1) We exclude stock-based compensation, which is non-cash, from the non-GAAP financial measures because the Company believes that such exclusion provides a better comparison of results of ongoing operations for current and future periods with such results from past periods.
(2) On February 14, 2020, our Board of Directors approved a global restructuring plan (the “Restructuring Plan”), which is intended to support our strategic plan in an effort to improve operating performance and ensure that we are appropriately structured and resourced to deliver increased and sustainable value to our shareholders and customers. On February 7, 2023, our Board of Directors approved an integration plan (the “Integration Plan”), which is intended to streamline and simplify operations, particularly around our recent acquisitions and the resulting redundant operations and offerings. The Restructuring and other costs primarily consist of severance and related benefits associated with the Restructuring Plan, Integration Plan, and executive transitions.
(3) The Income tax effect of non-GAAP adjustments is calculated by applying a statutory tax rate to Non-GAAP adjustments, including Stock-based compensation, Restructuring and other costs, non-recurring Inventory reserve charges, and Purchase accounting intangible amortization and fair value adjustments. In addition, when estimating our Non-GAAP income tax rate, we exclude the impact of items that impact our reported income tax rate that we do not believe are representative of our ongoing operating results, including the impact of valuation allowances we are currently recording in certain jurisdictions and certain discrete items such as adjustments to uncertain tax position reserves, as these items are difficult to predict and can impact our effective income tax rate. Specifically, Other tax adjustments during the six months ended June 30, 2024 were comprised of $3.6 million related to the impact of valuation allowance adjustments and $0.3 million related to other discrete items. During the three months ended June 30, 2024, Other tax adjustments were comprised of $0.8 million related to the impact of valuation allowance adjustments and $0.3 million related to other discrete items. In 2023, Other tax adjustments during the six months ended June 30, 2023 were comprised of $9.2 million related to the impact of valuation allowance adjustments and $5.3 million related to other items, including equity based compensation book to tax differences, non-GAAP adjustments impact on Global intangible low-taxed income and Prepaid tax on intercompany profit. During the three months ended June 30, 2023, Other tax adjustments were comprised of $4.6 million related to the impact of valuation allowance adjustments and $3.4 million related to other items, including equity based compensation book to tax differences, non-GAAP adjustments impact on Global intangible low-taxed income and Prepaid tax on intercompany profit.
FARO TECHNOLOGIES, INC. AND SUBSIDIARIES
RECONCILIATION OF NET INCOME (LOSS) TO EBITDA AND ADJUSTED EBITDA
(UNAUDITED)
Three Months Ended June 30,
Six Months Ended June 30,
(in thousands)
2024
2023
2024
2023
Net loss
$ (524)
$ (28,245)
$ (7,791)
$ (49,409)
Interest expense, net
761
1,003
1,592
1,838
Income tax expense
1,556
1,416
2,657
3,349
Depreciation and amortization
4,167
3,947
7,788
7,925
EBITDA
5,960
(21,879)
4,246
(36,297)
Other expense (income), net
(43)
476
(18)
256
Stock-based compensation
1,164
4,950
5,703
8,584
Restructuring and other costs (1)
1,361
9,244
4,072
14,712
Adjusted EBITDA
$ 8,442
$ (7,209)
$ 14,003
$ (12,745)
Adjusted EBITDA margin (2)
10.3 %
1.0 %
8.4 %
(2.7) %
(1) On February 14, 2020, our Board of Directors approved the Restructuring Plan, which is intended to support our strategic plan in an effort to improve operating performance and ensure that we are appropriately structured and resourced to deliver increased and sustainable value to our shareholders and customers. On February 7, 2023, our Board of Directors approved the Integration Plan, which is intended to streamline and simplify operations, particularly around our recent acquisitions and the resulting redundant operations and offerings. The Restructuring and other costs primarily consist of severance and related benefits associated with the Restructuring Plan, Integration Plan, and executive transitions.
(2) Calculated as Adjusted EBITDA as a percentage of total sales.
FARO TECHNOLOGIES, INC. AND SUBSIDIARIES
KEY SALES MEASURES
(UNAUDITED)
Three Months Ended June 30,
Six Months Ended June 30,
(in thousands)
2024
2023
2024
2023
Total sales to external customers as reported
Americas (1)
$ 40,167
$ 41,358
$ 77,395
$ 83,701
EMEA (1)
24,600
24,855
50,035
49,020
APAC (1)
17,318
21,998
38,899
40,457
$ 82,085
$ 88,211
$ 166,329
$ 173,178
Three Months Ended June 30,
Six Months Ended June 30,
(in thousands)
2024
2023
2024
2023
Total sales to external customers in constant currency (2)
Americas (1)
$ 40,425
$ 41,482
$ 77,714
$ 83,210
EMEA (1)
24,931
24,964
50,395
47,860
APAC (1)
17,783
21,446
39,552
38,544
$ 83,139
$ 87,892
$ 167,661
$ 169,614
(1) Regions represent North America and South America (“Americas”); Europe, the Middle East, and Africa (“EMEA”); and the Asia-Pacific (“APAC”).
(2) We compare the change in the sales from one period to another period using constant currency disclosure. We present constant currency information to provide a framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. To present this information, current and comparative prior period results for entities reporting in currencies other than United States dollars are converted into United States dollars at the exchange rate in effect during the last day of the prior comparable period, rather than the actual exchange rates in effect during the respective periods.
Three Months Ended June 30,
Six Months Ended June 30,
(in thousands)
2024
2023
2024
2023
Hardware
$ 50,051
$ 56,816
$ 102,667
$ 111,778
Software
11,262
10,786
22,182
21,065
Service
20,772
20,609
41,480
40,335
Total Sales
$ 82,085
$ 88,211
$ 166,329
$ 173,178
Hardware as a percentage of total sales
61.0 %
64.4 %
61.7 %
64.5 %
Software as a percentage of total sales
13.7 %
12.2 %
13.3 %
12.2 %
Service as a percentage of total sales
25.3 %
23.4 %
24.9 %
23.3 %
Total Recurring Revenue (3)
$ 17,139
$ 16,396
$ 33,856
$ 33,081
Recurring revenue as a percentage of total sales
20.9 %
18.6 %
20.4 %
19.1 %
(3) Recurring revenue is comprised of hardware service contracts, software maintenance contracts, and subscription based software applications.
FARO TECHNOLOGIES, INC. AND SUBSIDIARIES
FREE CASH FLOW RECONCILIATION
(UNAUDITED)
Three Months Ended June 30,
Six Months Ended June 30,
(in thousands)
2024
2023
2024
2023
Net cash provided by (used in) operating activities
$ 4,212
$ 5,137
$ 10,787
$ (13,207)
Purchases of property and equipment
(365)
(2,624)
(1,688)
(4,312)
Cash paid for technology development, patents and licenses
(1,950)
(1,796)
(3,392)
(3,616)
Free Cash Flow
1,897
717
5,707
(21,135)
Restructuring and other cash payments (1)
2,354
3,192
2,757
3,988
Adjusted Free Cash Flow
$ 4,251
$ 3,909
$ 8,464
$ (17,147)
(1) On February 7, 2023, our Board of Directors approved the Integration Plan, which is intended to streamline and simplify operations, particularly around our recent acquisitions and the resulting redundant operations and offerings. The Restructuring and other costs primarily consist of severance and related benefits associated with the Restructuring Plan, Integration Plan, and executive transitions.
FARO TECHNOLOGIES, INC. AND SUBSIDIARIES
RECONCILIATION OF OUTLOOK – GAAP TO NON-GAAP
Fiscal quarter ending September 30, 2024
Low
High
GAAP gross margin
53.0 %
54.5 %
Stock-based compensation
0.5 %
0.5 %
Non-GAAP gross margin
53.5 %
55.0 %
Fiscal quarter ending September 30, 2024
(in thousands)
Low
High
GAAP operating expenses
$45,000
$47,000
Stock-based compensation
(4,000)
(4,000)
Purchase accounting intangible amortization
(1,000)
(1,000)
Non-GAAP operating expenses
$40,000
$42,000
Fiscal quarter ending September 30, 2024
Low
High
GAAP diluted loss per share range
$(0.32)
$(0.12)
Stock-based compensation
0.19
0.19
Purchase accounting intangible amortization
0.05
0.05
Non-GAAP tax adjustments
0.07
0.07
Non-GAAP diluted loss per share
$(0.01)
$0.19
View original content to download multimedia:https://www.prnewswire.com/news-releases/faro-announces-second-quarter-financial-results-302218336.html
SOURCE FARO Technologies
You may like
Technology
Tech employment ends year with uptick in hiring, CompTIA analysis finds
Published
23 minutes agoon
January 10, 2025By
Tech unemployment rate falls to 2%
DOWNERS GROVE, Ill., Jan. 10, 2025 /PRNewswire/ — Tech hiring increased during the latest jobs data release, resulting in a corresponding decrease in the tech unemployment rate, CompTIA, the world’s leading provider of vendor-neutral information technology (IT) training and certification products, reported today.
Analysis of U.S. Bureau of Labor Statistics (BLS) #JobsReport data reveals the tech unemployment rate dropped to 2% in December, the lowest level since November 2023. The national unemployment rate was essentially unchanged at 4.1% for the month.
The base of tech employment throughout the economy increased by a net new 7,000 positions. In the aggregate the core tech workforce totals nearly 6.5 million workers.¹
Employment within the technology industry sector, encompassing all types of workers, declined by 6,117 jobs.² Positions in PC, semiconductor and components manufacturing accounted for the bulk of the cuts. The tech sector employs nearly 5.6 million people, which translates to a percentage decline of 1%.
“This marks the 100th release of the CompTIA Tech Jobs report,” noted Tim Herbert, chief research officer, CompTIA. “What an incredible journey in tracking tech workforce trends over the past decade. A true honor to be at the center of such an innovative and dynamic space.”
There were 434,415 active employer job postings for tech positions in December, including 165,189 newly added during the month.³ Both totals were down from November. Positions in software development and engineering, IT project management, cybersecurity, data science and analysis and tech support had the most activity.
Companies with the largest numbers of December job postings included Amazon, Accenture, Deloitte, PricewaterhouseCoopers, GovCIO, Robert Half, Lumen Technologies and Insight Global.
Employers listed open positions at all career levels. Among postings that specified a work experience requirement, 22% sought candidates with 0-3 years of experience; 28% of openings sought workers with 4-7 years of experience; and 16%, 8 years or more.
Across all tech occupations 45% of December job postings did not specify a four-year degree requirement for applicants. Openings for network support specialists (85%), tech support specialists (72%) and computer programmers (54%) had notably higher percentages.
The “CompTIA Tech Jobs Report” is available at https://www.comptia.org/content/tech-jobs-report.
About CompTIA
CompTIA Inc. is the world’s leading provider of vendor-neutral information technology (IT) training and certification products. CompTIA unlocks potential in millions of aspiring technology professionals and careers changers. Working in partnership with thousands of academic institutions and training providers, CompTIA helps students build career-ready skills through best-in-class learning solutions, industry-recognized certifications and career resources.
Learn more at https://www.comptia.org/.
Media Contact
Steven Ostrowski
CompTIA
sostrowski@comptia.org
+1.630.678.8468
¹ Monthly occupation level data from the U.S. Bureau of Labor Statistics tends to experience higher levels of variance and volatility.
² Labor market data from the U.S. Bureau of Labor Statistics and employer job postings from Lightcast may be subject to backward revisions.
³ Active job postings include open postings carried over from previous months and new postings added by employers.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tech-employment-ends-year-with-uptick-in-hiring-comptia-analysis-finds-302348198.html
SOURCE CompTIA
Technology
Iktos and Cube Biotech Announce Launch of Small Molecule AI Drug Discovery Collaboration
Published
23 minutes agoon
January 10, 2025By
Partnership will leverage Iktos’s AI-enabled drug discovery platform and Cube Biotech’s advanced protein technologies to develop novel agonists of the Amylin Receptor
PARIS and MONHEIM, Germany, Jan. 10, 2025 /PRNewswire/ — Iktos, a leader in Artificial Intelligence (AI) and Robotics for drug design, and Cube Biotech, a pioneer in membrane protein production and purification technologies, today announced a strategic collaboration to discover novel small molecule agonists of the Amylin Receptor.
The partnership combines Iktos’ generative AI-driven drug discovery and robotic synthesis platform with Cube Biotech’s advanced native membrane protein technology NativeMPTM, as well as their purification and biophysical assay expertise, to accelerate the development of breakthrough therapies. This paves the way for a joint collaborative offering directed towards pharmaceutical companies, combining the strengths of both platforms to undertake their most challenging drug discovery programs.
Amylin receptor agonists hold significant promise for addressing unmet medical needs in cardiometabolic disorders, including obesity, diabetes, and metabolic dysfunction-associated steatotic hepatitis (MASH). The Amylin Receptor regulates appetite and satiety, making it a compelling target for obesity, which affects over one-third of the global population. Existing GLP-1 receptor agonist therapies like semaglutide or the peptide Amylin analogue Pramlintide have limited impact due to high costs, accessibility, and undesirable side effects.
Orally administered novel small molecule agonists of the Amylin receptor could overcome these barriers, offering scalable and effective treatments and providing better management for the growing obesity epidemic and its comorbidities. However, the receptor’s structural and biological complexity has long posed challenges for discovering viable low-molecular-weight modulators.
“By tackling one of the most pressing unmet needs in cardiometabolic disorders, our partnership with Cube Biotech aims to discover improved treatments for patients affected by obesity, diabetes, and related conditions,” said Yann Gaston-Mathé, Co-founder and CEO of Iktos. “We are excited to add the Amylin Receptor to our pipeline as this complex, yet promising target demands innovation at every stage. We see this collaboration as a foundation for future initiatives, extending the reach of our combined platform to address the most challenging membrane targets for the benefit of our pharma partners.”
Iktos has developed a cutting-edge 3D generative chemistry technology for structure-guided de novo design that natively accounts for protein flexibility during molecule optimization—a key advantage over models like AlphaFold, which can only be applied post-molecule generation. Cube Biotech has developed a world-leading protein production platform, based on NativeMP™ technology, which preserves the natural configuration of membrane proteins – a key advantage in accessing biologically active drug targets for testing. The company’s native protein stabilization technology enhances the reliability and precision of functional assays, structural insights, and downstream applications.
“Amylin Receptor is a challenging but highly promising target for metabolic disorders”, said Dr. Barbara Maertens, Co-founder and COO of Cube Biotech. “Through our collaboration with Iktos, we aim to leverage our advanced protein stabilization and structural analysis technologies to validate and accelerate the discovery of novel small molecule agonists. Together, we are setting a new standard for efficiency and innovation in drug discovery.”
These integrated technologies endeavor to overcome longstanding inefficiencies in drug discovery, shortening timelines, improving success rates, and unlocking new possibilities for targeting complex and historically elusive membrane proteins, such as G-protein coupled receptors (GPCRs), membrane transporters, ion channels, and others.
About Iktos
Iktos is a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos’ proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI).
About Cube Biotech Cube Biotech is a leader in membrane protein production, purification, and characterization technologies. With proprietary copolymer-based solutions that maintain biological integrity in native-like protein states, Cube Biotech enables groundbreaking research in challenging drug targets, including membrane receptors, protein co-expressions, and even larger complexes.
The company’s expertise in assay development, biophysical characterization, and structural resolution supports efficient drug discovery workflows across the pharmaceutical and biotechnical industries. Additionally, an extensive purification resin and magnetic bead portfolio for affinity chromatography and efficient protein purification is manufactured in-house at high quality. For more information, visit www.cube-biotech.com.
Media Contact:
Eleonora Echegaray
P: 35 823189279
E: 388591@email4pr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/iktos-and-cube-biotech-announce-launch-of-small-molecule-ai-drug-discovery-collaboration-302348215.html
SOURCE Iktos
Technology
Rule 10b-5 Private Securities-Fraud Litigation Peaked in 4Q’24
Published
23 minutes agoon
January 10, 2025By
BETHESDA, Md., Jan. 10, 2025 /PRNewswire/ — SAR, a data analytics company specialized in the securities litigation risk of U.S. public companies, today published the Securities Class Action Rule 10b-5 Exposure Report for 4Q 2024. According to the report, securities litigation exposure of public company defendants that trade in the NYSE and NASDAQ peaked during the fourth quarter of 2024, when records were set across the buoyant U.S. equity markets. During the bullish market conditions of 2024, shareholders claimed approx. $665.2 billion in market capitalization losses due to alleged violations of Rule 10b-5 – the most in the last five years.
According to the report, global quarterly Rule 10b-5 securities litigation exposure in 2024 was 17% greater than the average of 2023. Actual monetary settlements with investor plaintiffs last year were, on average, 23% greater than during the last six years.
SAR data and analysis indicate that the litigation exposure of U.S. public company defendants amounts to approximately $380.3 billion in 2H 2024. Shareholders claimed approximately $4.0 billion in market capitalization losses per securities class action filing, and approximately $2.0 billion per allegedly fraud-related stock drop in 2H 2024. The former metric increased by 32.1%, and the latter by 15.4% during the second half of 2024.
“Our data and analyses indicate that securities litigation exposure against U.S. public companies peaked in the fourth quarter of last year. This peak may be short-lived with an expected increase in volatility and new headwinds for U.S. equities given greater shareholder scrutiny of corporate disclosures. With average Rule 10b-5 settlements over 20% greater in 2024 than during the last six years, litigation activity is expected to increase in 2025,” said Anthony Kabanek, EVP of SAR.
According to the report, in 2023 and 2024 investor plaintiffs claimed $13.6 billion and $20.5 billion, respectively, in private Rule 10b-5 securities-fraud class actions that relied on short-seller research.
Key takeaways:
86 U.S. issuers were sued for alleged violations of Rule 10b-5 during 2H 2024. Based on allegations presented in the first-filed class action complaint against each defendant issuer, U.S. SCA Rule 10b-5 Exposure amounts to $259.4 billion. U.S. SCA Rule 10b-5 Exposure decreased -5.4% relative to 1H 2024.
U.S. SCA Rule 10b-5 Exposure peaked in the 2nd and 3rd quarters, followed by a decline to trend in the 4th quarter of 2024.
9 Non-U.S. issuers were sued for alleged violations of Rule 10b-5 during 2H 2024. Based on allegations presented in the first-filed class action complaint against each defendant issuer, ADR SCA Rule 10b-5 Exposure amounts to $120.9 billion. ADR SCA Rule 10b-5 Exposure increased by 11.3x relative to 1H 2024.
An anomalously high 4th quarter exposure among Non-U.S. issuers contributed to a remarkably volatile year for ADR SCA Rule 10b-5 Exposure.
Rule 10b-5 private securities-fraud filing frequency and potential loss severity need not move in tandem. Global exposure increased by approximately 34% in the 2H 2024 relative to 1H 2024, while filing frequency remained relatively stable.
38 U.S. Large Caps were sued for alleged violations of Rule 10b-5 in 2H 2024, the same observed frequency as 1H 2024. The U.S. Large Cap SCA Rule 10b-5 Exposure amounts to $233.7 billion, a decrease of 10.1% relative to 1H 2024.
22 U.S. Mid Caps were sued for alleged violations of Rule 10b-5 In 2H 2024. The U.S. Mid Cap SCA Rule 10b-5 Exposure amounts to $19.8 billion, more than 3 times the amount in 1H 2024.
26 U.S. Small Caps were sued for alleged violations of Rule 10b-5. The U.S. Small Cap SCA Rule 10b-5 Exposure amounts to $5.9 billion, a decrease of 33% relative to 1H 2024.
9 Non-U.S. issuers that trade via ADRs in the U.S. public markets were sued for alleged violations of Rule 10b-5. The ADR SCA Rule 10b-5 Exposure increased by over 11.3x to ~$121 billion, relative to 1H 2024.
Media contact: info@sarlit.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rule-10b-5-private-securities-fraud-litigation-peaked-in-4q24-302348187.html
SOURCE SAR
Tech employment ends year with uptick in hiring, CompTIA analysis finds
Iktos and Cube Biotech Announce Launch of Small Molecule AI Drug Discovery Collaboration
Rule 10b-5 Private Securities-Fraud Litigation Peaked in 4Q’24
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Peloton Unveils Holiday 2022 Creative Campaign Highlighting How Motivation Transcends Beyond the Workout
These ’90s fashion trends are making a comeback in 2017
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days ago
“Rock a New Era”: Roborock Revolutionises Smart Home Cleaning at CES 2025 with robotic arm equipped Saros Z70
-
Technology5 days ago
Amorepacific Named CES 2025 Innovation Award Honoree
-
Coin Market5 days ago
Mining company MARA lent out 7,377 BTC to third parties in 2024
-
Technology5 days ago
NIKON EXHIBITS AT CES 2025
-
Coin Market4 days ago
Toyota’s AI and Robotics-powered ‘Woven City’ set to open this year
-
Technology5 days ago
Audio Foundry Unveils at CES 2025: Primax-Tymphany Group Drives Innovation in Smart Vehicle Technology
-
Technology5 days ago
Tencent Cloud Recognized Again in the Gartner® “Competitive Landscape: Video Platform Services” Report, solidifying its Pioneering Position in the Asia-Pacific Market
-
Technology5 days ago
Movate Appoints Industry Veteran Srijit Menon as Chief Revenue Officer for Digital Services to Drive Strategic Growth and Transformation